# A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05488314/  
OnCo record `nct05488314` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Capmatinib and Amivantamab in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05488314 by Janssen Research & Development, LLC, with 57 participants enrolled, started 2022-12-13 and due to reach its primary completion in 2027-04-28. Interventions recorded: Capmatinib and Amivantamab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05488314
- Phase: 1/2
- Setting: A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT05488314: https://clinicaltrials.gov/study/NCT05488314

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Capmatinib](https://onco.cc/drugs/capmatinib/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct05488314.json